journal article·2022-12

Discrete single-cell microRNA analysis for phenotyping the heterogeneity of acute myeloid leukemia

Xi Zhao, Zixun Wang, Xianglin Ji, Shuyu Bu, Peilin Fang, Yuan Wang, Mingxue Wang, Yang Yang, Wenjun Zhang, Anskar Y.H. Leung, Peng Shi

Biomaterials· Volume 291
Publisher page

Abstract

Acute myeloid leukemia (AML) is a highly heterogenous cancer in hematopoiesis, and its subtype specification is greatly important in the clinical practice for AML diagnosis and prognosis. Increasing evidence has shown the association between microRNA (miRNA) phenotype and AML therapeutic outcomes, emphasizing the need for novel techniques for convenient, sensitive, and efficient miRNA profiling in clinical practices. Here, we describe a nanoneedle-based discrete single-cell microRNA profiling technique for multiplexed phenotyping of AML heterogeneity without the requirement of sequencing or polymerase chain reaction (PCR). In virtue of a biochip-based and non-destructive nature of the assay, the expression of nine miRNAs in large number of living AML cells can be simultaneously analyzed with discrete single-cell level information, thus providing a proof-of-concept demonstration of an AML subtype classifier based on the multidimensional miRNA data. We showed successful analysis of subtype-specific cellular composition with over 90% accuracy and identified drug-responsive leukemia subpopulations among a mixed suspension of cells modeling different AML subtypes. The adoption of machine learning algorithms for processing the large-scale nanoneedle-based miRNA data shows the potential for powerful prediction capability in clinical applications to assist therapeutic decisions. We believe that this platform provides an efficient and cost-effective solution to move forward the translational prognostic usage of miRNAs in AML treatment and can be readily and advantageously applied in analyzing rare patient-derived clinical samples.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Acute myeloid leukemia: a concise review10.3390/jcm5030033 ↗
2. Genetic and epigenetic heterogeneity in acute myeloid leukemia10.1016/j.gde.2016.03.011 ↗
3. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts10.1182/blood-2016-10-697698 ↗
4. MicroRNAs: small RNAs with a big role in gene regulation10.1038/nrg1379 ↗
5. The prognostic and functional role of microRNAs in acute myeloid leukemia10.1182/blood-2010-09-191312 ↗
6. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling10.1182/asheducation-2017.1.37 ↗
7. MicroRNAs as new biomarkers for diagnosis and prognosis, and as potential therapeutic targets in acute myeloid leukemia10.3390/ijms19020460 ↗
8. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia10.1038/s41375-020-01095-z ↗
9. Serum microRNAs as powerful cancer biomarkers10.1016/j.bbcan.2010.07.002 ↗
10. Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition10.1126/sciadv.abj1664 ↗
11. Considerations for the use of transcriptomics in identifying the ‘genes that matter’for environmental adaptation10.1242/jeb.114306 ↗
12. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory10.1080/10408363.2017.1410520 ↗
13. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis10.3390/cells9020276 ↗
14. In vitro application of ribonucleases: comparison of the effects on mRNA and miRNA stability10.1186/s13104-015-1114-z ↗
15. Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries10.1186/gb-2011-12-2-r18 ↗
16. RNA sequencing: new technologies and applications in cancer research10.1186/s13045-020-01005-x ↗
17. The technology and biology of single-cell RNA sequencing10.1016/j.molcel.2015.04.005 ↗
18. Interrogation of cellular innate immunity by diamond-nanoneedle-assisted intracellular molecular fishing10.1021/acs.nanolett.5b03126 ↗
19. High-throughput intracellular biopsy of microRNAs for dissecting the temporal dynamics of cellular heterogeneity10.1126/sciadv.aba4971 ↗
20. Poking cells for efficient vector-free intracellular delivery10.1038/s41467-024-52768-7 ↗
21. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8; 21 chromosome translocation10.1182/blood.V77.9.2031.2031 ↗
22. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins (11; 9)(q23; p22p23)10.1038/sj.leu.2400768 ↗
23. Lanotte · 1991
24. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients10.1200/JCO.2012.45.6228 ↗
25. The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα10.1038/leu.2015.117 ↗
26. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
27. Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation10.1038/s41409-018-0146-0 ↗
28. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia10.1073/pnas.0709313104 ↗
29. Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia10.1186/2162-3619-3-17 ↗
30. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study10.1200/JCO.2010.29.2953 ↗
31. Differential expression of specific microRNA and their targets in acute myeloid leukemia10.1002/ajh.21667 ↗
32. MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways10.1371/journal.pone.0056334 ↗
33. Hsu · 2014
34. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias10.1016/j.leukres.2007.04.013 ↗
35. Acute myeloid leukemia: current progress and future directions10.1038/s41408-021-00425-3 ↗
36. RNA biomarkers: frontier of precision medicine for cancer10.3390/ncrna3010009 ↗
37. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations10.1073/pnas.0808266105 ↗
38. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia10.1016/j.clinbiochem.2012.09.002 ↗
39. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis10.1038/sj.leu.2404605 ↗
40. High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome
41. Profiling MicroRNAs with associated spatial dynamics in acute tissue slices10.1021/acsnano.0c09676 ↗
42. Acute myeloid leukemia immunophenotyping by flow cytometric analysis10.1016/j.cll.2017.07.003 ↗
43. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity10.1016/j.cell.2019.01.031 ↗
44. Artificial intelligence and machine learning in clinical development: a translational perspective10.1038/s41746-019-0148-3 ↗
45. Studying and modelling dynamic biological processes using time-series gene expression data10.1038/nrg3244 ↗
46. Proliferation dynamics of acute myeloid leukaemia and haematopoietic progenitors competing for bone marrow space10.1038/s41467-017-02376-5 ↗
47. Dynamics of drug response informs rational combination regimens10.1126/scisignal.aax9742 ↗
48. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency10.1016/j.jcyt.2018.10.014 ↗
49. Size selective recognition of siRNA by an RNA silencing suppressor10.1016/S0092-8674(03)00984-X ↗